Lowers FY23 revenue view to $1.541B-$1.547B from $1.548B-$1.560B. The revenue range represents reported growth of -1.1% to -0.7%, with organic growth of 0.1% to 0.5%, reflecting the impact of higher-than-expected Boston recall returns, strong organic growth excluding Boston, the strength of the U.S. dollar, and an updated tax rate.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IART:
- Integra LifeSciences Reports Third Quarter 2023 Financial Results
- IART Upcoming Earnings Report: What to Expect?
- Integra LifeSciences price target lowered to $41 from $48 at Truist
- Integra LifeSciences to Host Third Quarter 2023 Financial Results Conference Call on October 25, 2023
- Integra LifeSciences to Present at the 2023 Wells Fargo Healthcare Conference
